Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

April 25, 2017

DoD’s plans to grant an exclusive license to pharmaceutical company Sanofi on a vaccine candidate funded by the US government to combat Zika means there’s no guarantee that the vaccine will be developed, affordable or made available for those who need it most

March 27, 2017

First patent opposition MSF has filed in Europe aims to increase affordable access to hepatitis C drug sofosbuvir for millions

NEW YORK/ROME/GENEVA, MARCH 27, 2017—In an effort to increase access to affordable hepatitis C treatment, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a patent challenge on the lifesaving hepatitis C drug sofosbuvir with the European Patent Office (EPO) today.

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

March 23, 2017

Companies and countries must take urgent action to increase access to these lifesaving treatments

March 08, 2017
WASHINGTON, MARCH 8, 2017—Judit Rius Sanjuan, Doctors Without Borders/Médecins Sans Frontières’ (MSF) Access Campaign manager and legal policy advisor, delivered the following remarks at the United States Trade Representative's 2017 Special 301 Review hearing today.
 
Good afternoon. I would like to provide testimony on behalf of MSF.
March 02, 2017

Key House subcommittee examined bill today that amends neglected disease innovation incentive program without fixing loopholes abused by pharmaceutical corporations

February 27, 2017

The World Health Organization (WHO) announced today its first ever list of antibiotic-resistant bacteria that pose the greatest threats to public health. The list aims to encourage and mobilize innovators to conduct research and development on new antibiotics.

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.

January 24, 2017

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability

November 16, 2016

Pfizer and GlaxoSmithKline (GSK) should extend their price reduction to all developing countries

Pages